Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2021 · 10-Q
Revenue$2.22M$2.22M−83.4% vs Q2 2020 Net Income-$22.11M-$22.11MN/M vs Q2 2020 EPS Diluted-$0.51-$0.51— vs Q2 2020 Operating Income-$22,498,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,986,000N/M Margins · derivedOperating margin-1014.3%−1009.5 pt vs Q2 2020
Net margin-996.8%−995.5 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end